There is a brief summary posted today on the MDS Beacon Site that has updated overall survival for some higher-risk patients treated with Vadaza.
In summary "... median overall survival was 31 months for intermediate-risk patients, 18 months for high-risk patients, and 10 months for very high-risk patients ... using only the chromosomal abnormalities criteria of the IPSS-R, they also found ... median overall survival was 22 months for patients with good chromosomal abnormalities, 12 months for patients with intermediate chromosomal abnormalities, 15 months for patients poor chromosomal abnormalities, and 7 months for patients with very poor chromosomal abnormalities."
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%
)
47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).